Cargando…
MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer
Elevated expression of Survivin correlates with poor prognosis, tumor recurrence, and drug resistance in various human cancers, including non-small cell lung cancer (NSCLC). The underlying mechanism of Survivin upregulation in cancer cells remains elusive. To date, no Survivin-targeted therapy has b...
Autores principales: | Wang, Shuiliang, Zhu, Ling, Zuo, Weimin, Zeng, Zhiyong, Huang, Lianghu, Lin, Fengjin, Lin, Rong, Wang, Jin, Lu, Jun, Wang, Qinghua, Lin, Lingjing, Dong, Huiyue, Wu, Weizhen, Zheng, Kai, Cai, Jinquan, Yang, Shunliang, Ma, Yujie, Ye, Shixin, Liu, Wei, Yu, Yinghao, Tan, Jianming, Liu, Bolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122342/ https://www.ncbi.nlm.nih.gov/pubmed/27177222 http://dx.doi.org/10.18632/oncotarget.9264 |
Ejemplares similares
-
Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer
por: Lyu, Hui, et al.
Publicado: (2018) -
Protein therapy using MafA fused to a polyarginine transduction domain attenuates glucose levels of streptozotocin-induced diabetic mice
por: Lu, Jun, et al.
Publicado: (2017) -
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019) -
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013) -
Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT
por: Cai, Yuanming, et al.
Publicado: (2019)